腹膜是结直肠癌转移的第二好发部位，长期以来被视为预后最差的结直肠癌转移类型，主要采用姑息性手段治疗。尽管化疗及靶向治疗在结直肠癌治疗上大有进展，但对于腹膜转移的结直肠癌疗效并不理想。最近越来越多的证据表明，肿瘤细胞减灭术(cytoreductive surgery，CRS)与腹腔内热灌注化疗(hyperthermic intraperitoneal chemotherapy，HIPEC)相结合的治疗方法能给结直肠癌腹膜转移带来较大的生存获益，延长患者生存。本文综述了结直肠癌腹膜转移的机制、临床表现以及治疗的选择，重点阐述了CRS/HIPEC治疗方法的应用及其安全性和有效性的研究进展。而且还分析了本单位的CRS/HIPEC治疗结直肠癌腹膜转移的数据，提示CRS联合HIPEC是结直肠癌腹膜转移的一种安全有效的治疗模式。

Peritoneal carcinomatosis(PC)is the second most common presentation of colorectal cancer distant metastasis.Despite remarkable advances in cytotoxic chemotherapy and targeted therapy for colorectal cancer recently, it has been shown that these therapies remain ineffective for colorectal cancer PC.There have beensome reports that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy(CRS/HIPEC)improved the overall survival of colorectalcancer PC patients.Here, we reviewed the clinical presentation, the mechanisms of disease progression and current treatment options for colorectal cancer PC, with a focus on the benefits and limitations of CRS/HIPEC.Moreover, we collected the patients with colorectal cancer PC treated by CRS/HIPEC in our colorectal cancer center, and showed that morbidity and mortality of CRS/HIPEC is relatively low, and short-term quality of life may improve.In conclusion, CRS/HIPEC treatment modality has demonstrated short-term efficacy and security in colorectal cancer PC.